Navigation Links
U.S. District Court Rules from Bench in Lilly's Favor, Confirms Validity of Alimta Patent
Date:11/15/2010

INDIANAPOLIS, Nov. 15, 2010 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that the trial on the validity of the compound patent for Alimta® (pemetrexed for injection) before the U.S. District Court for the District of Delaware ended this afternoon with a ruling from the court that judgment would be entered in Lilly's favor, thereby upholding the patent's validity. The decision came in the case of Eli Lilly and Company et al v. Teva Parenteral Medicines Inc., et al. The patent provides protection for Alimta until July of 2016.

"We are pleased that the District Court has now confirmed the validity of Alimta's compound patent," said Robert A. Armitage, senior vice president and general counsel for Lilly. "We continue to emphasize that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. These rights provide assurances of market exclusivity that help support the development of the next generation of innovative medicines to treat unmet medical needs."

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  C-LLY

This release contains forward-looking statements regarding the U.S. Alimta patent litigation. These statements are based on management's current expectations but actual results may differ materially.  There can be no assurance that the company will prevail in any appeal.  Also, the company cannot predict whether generic pemetrexed will be marketed prior to the resolution of this litigation.  Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission.

Alimta® (pemetrexed, Lilly)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. German District Court Finds RENASYS™ GO NPWT System Non-infringing
2. Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System
3. Renhuang Wins Bid to Supply All-Natural Products to Guangzhou Military District
4. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
5. Occlutech Wins Dutch Appeal Court Ruling Against AGA Medical
6. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
7. Statement of Ben Anderson, Esq., Regarding Denial of Wyeths En Banc Petition to Sixth Circuit Court of Appeals in Major Drug Regulation Pre-emption Case
8. U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly
9. Supreme Court of Israel Rules in Favor of Sun Pharma
10. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
11. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 Research ... "Global Plastic Surgery Products Market 2016-2020" report to ... ) , The global plastic surgery products ... 9.47% during the period 2016-2020. , ,The growing adoption ... to the growth of the market. Lasers are used ...
(Date:4/28/2016)... , Net Sales of $1.90 billion represent ... prior year period, and an increase of 1.2% on an ... for the first quarter were $0.52 reported, a decrease of ... increase of 29.9% over the prior year period , ... for 2016 Zimmer Biomet Holdings, Inc. (NYSE and ...
(Date:4/28/2016)... , April 28, 2016 ... development of innovative peptide and gene-based immunotherapeutics and vaccines for ... will be presenting at the 3rd Annual Growth Capital ... 5 th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... am on Wednesday, May 4 th by Dr. ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... ... enterprise Data Center Infrastructure Management solutions, announces today the availability of its ... in the area of capacity management and optimization, providing new analytical capabilities ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing ... Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch in July ...
(Date:4/28/2016)... Cary, NC (PRWEB) , ... April 28, 2016 ... ... to announce it has partnered with Community Oncology Pharmacy Association (COPA) to develop ... elevate the practice of oncology by introducing an accreditation distinction. ACHC provides a ...
(Date:4/28/2016)... ... ... The Aging in Motion Coalition (AIM) has announced the Centers ... it recognition for separate reporting and data collection. The code, M62.84, will be available ... as a combination of low muscle mass and weakness in older adults that causes ...
(Date:4/28/2016)... ... 28, 2016 , ... The USDA recently released its updated Dietary Guidelines for ... While there is a lot of information available in the report, older men should ... issue of Harvard Men's Health Watch . , These include: , 1.    Vary ...
Breaking Medicine News(10 mins):